Cullinan Therapeutics, Inc.

CGEM

Cullinan Therapeutics, Inc.

CGEM

Insider Sentiment (TTM):

Last Purchase:2025-10-28Last Sale:2026-05-05Shares Purchased (TTM):475,182Shares Sold (TTM):116,012

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:62,999,122Shares Outstanding:60,462,000Institutional Ownership Pct.:104.20%

Earnings Market Reaction:

Filing Date:2026-08-06Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Assets
Assets Current
Cash And Cash Equivalents At Carrying Value	79	75	88	103	73	77	83	102	115	74	98	65
Short Term Investments	256	277	290	229	193	227	316	476	547	359	369	402
Prepaid Expense Current	7	10	9	10	10	14	16	14	15	13	13	10
Assets Current	342	361	387	342	276	318	415	592	678	446	480	477
Property Plant And Equipment Net	0	0	0	0	1	1	1	1	1	1	1	1
Operating Lease Right Of Use Asset	2	2	3	1	1	2	2	2	2	2	3	3
Other Assets Noncurrent	0	0	0	0	0	0	0	0	0	0	0	0
Long Term Investments	19	39	58	140	242	259	204	58	-	-	0	14
Assets	364	403	448	484	520	580	622	653	681	449	484	495
Liabilities And Stockhold…
Liabilities Current
Accounts Payable Current	4	3	1	2	2	3	2	2	2	4	2	1
Accrued Liabilities Current	36	32	36	30	24	23	28	21	21	17	24	21
Operating Lease Liability Current	1	1	1	1	1	1	1	1	1	1	1	2
Taxes Payable Current	-	-	-	-	-	-	-	-	-	-	0	0
Liabilities Current	41	35	38	33	28	27	31	24	23	22	28	23
Liabilities Noncurrent
Operating Lease Liability Noncurrent	1	2	2	0	0	0	1	1	2	2	2	2
Liabilities	42	37	40	33	28	28	31	25	25	24	30	26
Stockholders Equity Inclu…
Preferred Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Additional Paid In Capital Common Stock	1,013	1,004	996	988	978	968	959	947	937	664	655	647
Accumulated Other Comprehensive Income Loss Net Of…	-0	0	1	1	1	1	-0	1	-0	-0	-0	-1
Retained Earnings Accumulated Deficit	-691	-638	-588	-537	-487	-417	-368	-321	-280	-238	-201	-177
Stockholders Equity	322	366	409	451	492	552	590	628	656	426	454	469
Minority Interest	-	-	0	0	0	0	0	0	0	0	0	0
Liabilities And Stockholders Equity	364	403	448	484	520	580	622	653	681	449	484	495
Preferred Stock Par Or Stated Value Per Share	0	0	0	0	0	0	0	0	0	0	0	0
Preferred Stock Shares Authorized	10	10	10	10	10	10	10	10	10	10	10	10
Preferred Stock Shares Issued	0	0	1	1	1	1	1	1	1	1	1	1
Preferred Stock Shares Outstanding	0	0	1	1	1	1	1	1	1	1	1	1
Common Stock Par Or Stated Value Per Share	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Shares Authorized	150	150	150	150	150	150	150	150	150	150	150	150
Common Stock Shares Issued	64	61	60	59	59	59	59	58	58	43	43	43
Shares Outstanding	64	61	60	59	59	59	59	58	58	43	43	43

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2026	11.68%	25.00%	16.17%	-	-	-	-	-	-	-	-	-
2025	11.26%	-0.13%	5.28%	7.25%	-15.22%	10.38%	54.69%	41.09%	70.07%	-3.22%	-9.93%	10.26%
2024	-16.17%	-39.45%	-33.53%	19.66%	4.95%	-2.56%	-13.67%	-22.85%	-32.28%	-1.05%	-8.36%	-12.89%
2023	-	-	-	5.44%	-12.05%	-18.08%	-12.88%	2.52%	31.49%	0.65%	67.65%	38.97%
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 90+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Start free trial

Performance and Valuation Metrics

Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.

Metrics	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Liquidity Ratios
Current Ratio	8.42	10.28	10.25	10.45	9.83	11.62	13.53	24.46	28.87	20.33	17.07	20.33
Quick Ratio	8.23	10.01	10.01	10.15	9.46	11.11	13.02	23.88	28.22	19.75	16.60	19.90
Working Capital	301.35M	326.25M	349.02M	309.48M	247.85M	290.42M	384.02M	567.84M	654.32M	423.80M	452.05M	453.27M
Leverage & Debt
Debt to Equity	0.13	0.10	0.10	0.07	0.06	0.05	0.05	0.04	0.04	0.06	0.07	0.06
Debt Ratio	0.12	0.09	0.09	0.07	0.05	0.05	0.05	0.04	0.04	0.05	0.06	0.05
Efficiency & Turnover
Asset Turnover TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Per Share Metrics
Diluted EPS TTM	-	-3.67	-3.72	-3.59	-3.42	-2.95	-3.11	-2.46	-2.58	-3.08	-3.69	-3.65
Free Cash Flow Per Share TTM	-2.43	-2.96	-2.98	-2.22	-2.18	-2.55	-2.70	-2.17	-2.30	-2.83	-3.24	-3.33
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Growth Metrics
Net Income Growth (1Y)	1.66%	27.44%	31.36%	47.70%	42.06%	31.42%	9.28%	-8.07%	0.28%	-302.52%	-237.72%	-246.91%
EPS Growth (1Y)	-6.76%	24.16%	19.62%	45.86%	32.52%	-4.04%	-15.55%	-32.66%	-27.22%	-291.56%	-249.70%	-256.80%
Valuation Metrics
P/E TTM	-5.71	-3.88	-2.78	-1.65	-2.20	-2.56	-3.91	-6.80	-6.75	-5.54	-2.76	-2.48
P/B TTM	3.64	2.35	1.50	0.78	0.90	0.81	1.11	1.56	1.46	1.72	0.93	0.82
Market Cap	1.17B	859.17M	611.17M	350.31M	444.38M	445.91M	654.93M	976.56M	960.11M	732.91M	423.39M	386.74M
Enterprise Value	1.09B	784.08M	522.84M	246.98M	371.56M	369.26M	571.93M	874.48M	845.09M	658.68M	326.44M	322.07M
Calculated Values
Free Cash Flow TTM	-156.41M	-178.69M	-175.80M	-131.15M	-128.37M	-150.21M	-145.30M	-126.81M	-126.81M	-121.57M	-134.48M	-142.22M
Net Debt	-78.64M	-75.08M	-88.33M	-103.34M	-72.82M	-76.66M	-83.01M	-102.09M	-115.02M	-74.23M	-96.96M	-64.67M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
NCAV
NCAV Per Share TTM
Valuation Ratios
P/CF TTM
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2026-05-05Sale

Owner: Michaelson, Jennifer

Title: Chief Scientific Officer

Shares: 8,000

Price/Share: $15.09

Value: $120,720.00

Shares Owned: 166,844

Relationship: Officer

Ownership: Direct

2026-03-05Sale

Owner: Michaelson, Jennifer

Title: Chief Scientific Officer

Shares: 8,000

Price/Share: $15.68

Value: $125,440.00

Shares Owned: 170,844

Relationship: Officer

Ownership: Direct

2026-02-25Sale

Owner: Michaelson, Jennifer

Title: Chief Scientific Officer

Shares: 1,780

Price/Share: $14.14

Value: $25,169.20

Shares Owned: 174,844

Relationship: Officer

Ownership: Direct

2026-02-24Sale

Owner: Jones, Jeffrey Alan

Title: Chief Medical Officer

Shares: 4,582

Price/Share: $14.47

Value: $66,301.54

Shares Owned: 159,968

Relationship: Officer

Ownership: Direct

2026-02-24Sale

Owner: Michaelson, Jennifer

Title: Chief Scientific Officer

Shares: 3,601

Price/Share: $14.47

Value: $52,106.47

Shares Owned: 176,624

Relationship: Officer

Ownership: Direct

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2026-05-05	Michaelson, Jennifer	Officer	Chief Scientific Officer	Direct	Sale	8,000	15.09	$120,720.00	166,844	4
2026-03-05	Michaelson, Jennifer	Officer	Chief Scientific Officer	Direct	Sale	8,000	15.68	$125,440.00	170,844	4
2026-02-25	Michaelson, Jennifer	Officer	Chief Scientific Officer	Direct	Sale	1,780	14.14	$25,169.20	174,844	4
2026-02-24	Jones, Jeffrey Alan	Officer	Chief Medical Officer	Direct	Sale	4,582	14.47	$66,301.54	159,968	4
2026-02-24	Michaelson, Jennifer	Officer	Chief Scientific Officer	Direct	Sale	3,601	14.47	$52,106.47	176,624	4
2026-02-24	Ahmed, Nadim	Director,Officer	President and CEO	Direct	Sale	13,515	14.47	$195,562.05	390,803	4
2026-02-24	Sumer, Jacquelyn L	Officer	Chief Legal Officer	Direct	Sale	3,601	14.47	$52,106.47	128,089	4
2026-02-20	Fenton, Mary Kay	Officer	Chief Financial Officer	Direct	Sale	4,398	13.62	$59,900.76	126,380	4
2026-02-20	Sumer, Jacquelyn L	Officer	Chief Legal Officer	Direct	Sale	3,742	13.62	$50,966.04	131,690	4
2026-02-20	Jones, Jeffrey Alan	Officer	Chief Medical Officer	Direct	Sale	4,982	13.62	$67,854.84	164,550	4
2026-02-20	Ahmed, Nadim	Director,Officer	President and CEO	Direct	Sale	16,381	13.62	$223,109.22	404,318	4
2026-02-20	Michaelson, Jennifer	Officer	Chief Scientific Officer	Direct	Sale	11,742	13.96	$163,918.32	181,977	4
2026-02-12	Michaelson, Jennifer	Officer	Chief Scientific Officer	Direct	Sale	416	12.03	$5,004.48	128,219	4
2026-01-22	Michaelson, Jennifer	Officer	Chief Scientific Officer	Direct	Sale	4,000	12.30	$49,200.00	128,635	4
2025-12-23	Ahmed, Nadim	Director,Officer	President and CEO	Direct	Sale	9,922	10.01	$99,319.22	420,699	4
2025-12-19	Michaelson, Jennifer	Officer	Chief Scientific Officer	Direct	Sale	1,345	10.01	$13,463.45	132,635	4
2025-12-18	Jones, Jeffrey Alan	Officer	Chief Medical Officer	Direct	Sale	4,632	9.67	$44,791.44	169,532	4
2025-12-18	Sumer, Jacquelyn L	Officer	Chief Legal Officer	Direct	Sale	3,480	9.67	$33,651.60	135,432	4
2025-12-18	Michaelson, Jennifer	Officer	Chief Scientific Officer	Direct	Sale	2,898	9.67	$28,023.66	133,980	4
2025-12-15	Michaelson, Jennifer	Officer	Chief Scientific Officer	Direct	Sale	995	11.90	$11,840.50	136,878	4
2025-11-24	Michaelson, Jennifer	Officer	Chief Scientific Officer	Direct	Sale	4,000	12.30	$49,200.00	138,004	4
2025-10-28	Nichols, Weston, Lynx1 Ca…	TenPercentOwner	-	Indirect	Purchase	165,667	8.40	$1,391,602.80	8,963,500	4
2025-10-17	Lynx1, Capital Management…	TenPercentOwner	-	Indirect	Purchase	32,217	7.84	$252,581.28	8,797,833	4
2025-10-10	Lynx1, Capital Management…	TenPercentOwner	-	Indirect	Purchase	277,298	7.36	$2,040,913.28	8,549,084	4
2025-02-25	Ahmed, Nadim	Director,Officer	President and CEO	Direct	Sale	12,529	8.53	$106,872.37	430,621	4
2025-02-25	Jones, Jeffrey Alan	Officer	Chief Medical Officer	Direct	Sale	4,895	8.53	$41,754.35	174,164	4
2025-02-25	Sumer, Jacquelyn L	Officer	Chief Legal Officer	Direct	Sale	3,756	8.53	$32,038.68	136,895	4
2025-02-25	Michaelson, Jennifer	Officer	Chief Scientific Officer	Direct	Sale	3,756	8.53	$32,038.68	142,004	4
2025-01-06	Michaelson, Jennifer	Officer	Chief Scientific Officer	Direct	Sale	4,000	12.51	$50,040.00	95,760	4
2024-12-24	Ahmed, Nadim	Director,Officer	President and CEO	Direct	Sale	8,400	11.87	$99,708.00	263,150	4
2024-12-18	Jones, Jeffrey Alan	Officer	Chief Medical Officer	Direct	Sale	4,632	11.41	$52,851.12	114,059	4
2024-12-18	Sumer, Jacquelyn L	Officer	Chief Legal Officer	Direct	Sale	3,482	11.41	$39,729.62	90,651	4
2024-12-18	Michaelson, Jennifer	Officer	Chief Scientific Officer	Direct	Sale	4,693	11.41	$53,547.13	99,760	4
2024-12-12	Michaelson, Jennifer	Officer	Chief Scientific Officer	Direct	Sale	3,489	12.52	$43,682.28	104,453	4
2024-11-05	Michaelson, Jennifer	Officer	Chief Scientific Officer	Direct	Sale	8,000	15.64	$125,120.00	107,942	4
2024-09-05	Michaelson, Jennifer	Officer	Chief Scientific Officer	Direct	Sale	8,000	18.09	$144,720.00	115,942	4
2024-07-05	Michaelson, Jennifer	Officer	Chief Scientific Officer	Direct	Sale	8,000	16.33	$130,640.00	123,942	4
2024-05-07	Michaelson, Jennifer	Officer	Chief Scientific Officer	Direct	Sale	5,606	30.06	$168,516.36	129,582	4
2024-02-01	Savill, Corrine	Officer	Chief Business Officer	Direct	Sale	40,000	16.18	$647,200.00	165,990	4
2024-01-29	Savill, Corrine	Officer	Chief Business Officer	Direct	Sale	40,000	14.09	$563,600.00	165,990	4
2024-01-23	Savill, Corrine	Officer	Chief Business Officer	Direct	Sale	21,316	12.46	$265,597.36	165,990	4
2023-12-26	Ahmed, Nadim	Director,Officer	President and CEO	Direct	Sale	4,272	9.24	$39,473.28	111,550	4
2023-12-21	Michaelson, Jennifer	Officer	Chief Scientific Officer	Direct	Sale	1,145	8.50	$9,732.50	87,582	4
2023-12-21	Trigilio, Jeffrey	Officer	Chief Financial Officer	Direct	Sale	1,920	8.50	$16,320.00	83,919	4
2023-12-21	Jones, Jeffrey Alan	Officer	Chief Medical Officer	Direct	Sale	1,860	8.50	$15,810.00	56,191	4
2023-12-21	Sumer, Jacquelyn L	Officer	Chief Legal Officer	Direct	Sale	1,400	8.50	$11,900.00	44,133	4
2023-12-18	Sumer, Jacquelyn L	Officer	Chief Legal Officer	Direct	Sale	290	8.22	$2,383.80	45,533	4
2023-12-18	Jones, Jeffrey Alan	Officer	Chief Medical Officer	Direct	Sale	386	8.22	$3,172.92	58,051	4
2023-12-18	Michaelson, Jennifer	Officer	Chief Scientific Officer	Direct	Sale	238	8.22	$1,956.36	88,727	4
2023-12-18	Trigilio, Jeffrey	Officer	Chief Financial Officer	Direct	Sale	398	8.22	$3,271.56	85,839	4
2023-12-12	Trigilio, Jeffrey	Officer	Chief Financial Officer	Direct	Sale	1,926	7.81	$15,042.06	86,237	4
2023-12-12	Michaelson, Jennifer	Officer	Chief Scientific Officer	Direct	Sale	1,068	7.81	$8,341.08	88,965	4
2023-06-28	Ahmed, Nadim	Director,Officer	President and CEO	Direct	Sale	759	11.40	$8,652.60	115,822	4
2023-06-20	Jones, Jeffrey Alan	Officer	Chief Medical Officer	Direct	Sale	387	12.94	$5,007.78	58,437	4
2023-06-20	Michaelson, Jennifer	Officer	Chief Development Officer	Direct	Sale	238	12.94	$3,079.72	90,033	4
2023-06-20	Trigilio, Jeffrey	Officer	Chief Financial Officer	Direct	Sale	399	12.94	$5,163.06	85,823	4
2023-06-20	Sumer, Jacquelyn L	Officer	Chief Legal Officer	Direct	Sale	291	12.94	$3,765.54	45,823	4
2023-06-12	Trigilio, Jeffrey	Officer	Chief Financial Officer	Direct	Sale	319	13.11	$4,182.09	86,222	4
2023-06-12	Michaelson, Jennifer	Officer	Chief Development Officer	Direct	Sale	176	13.11	$2,307.36	90,271	4
2023-06-07	Michaelson, Jennifer	Officer	Chief Development Officer	Direct	Sale	100	12.40	$1,240.00	90,447	4
2023-05-23	Ahmed, Nadim	Director,Officer	President and CEO	Direct	Sale	707	9.15	$6,469.05	116,581	4
2023-05-18	Trigilio, Jeffrey	Officer	Chief Financial Officer	Direct	Sale	399	8.76	$3,495.24	86,541	4
2023-05-18	Jones, Jeffrey Alan	Officer	Chief Medical Officer	Direct	Sale	394	8.76	$3,451.44	58,824	4
2023-05-18	Sumer, Jacquelyn L	Officer	Chief Legal Officer	Direct	Sale	291	8.76	$2,549.16	46,114	4
2023-05-18	Michaelson, Jennifer	Officer	Chief Development Officer	Direct	Sale	239	8.76	$2,093.64	90,447	4
2023-05-12	Michaelson, Jennifer	Officer	Chief Development Officer	Direct	Sale	193	8.78	$1,694.54	90,686	4
2023-05-12	Trigilio, Jeffrey	Officer	Chief Financial Officer	Direct	Sale	347	8.78	$3,046.66	86,940	4
Additional insider transactions are for subscribers only. Unlock the complete Form 4 filing history Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2026-03-31

104.20%

Inst. Shares: 62,999,122

Shares Outstanding: 60,462,000

2025-12-31

106.40%

Inst. Shares: 62,831,420

Shares Outstanding: 59,050,000

2025-09-30

102.80%

Inst. Shares: 60,727,632

Shares Outstanding: 59,075,000

2025-06-30

105.06%

Inst. Shares: 62,003,136

Shares Outstanding: 59,015,000

2025-03-31

108.61%

Inst. Shares: 63,975,041

Shares Outstanding: 58,905,000

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	62,999,122	60,462,000	104.20%
2025-12-31	62,831,420	59,050,000	106.40%
2025-09-30	60,727,632	59,075,000	102.80%
2025-06-30	62,003,136	59,015,000	105.06%
2025-03-31	63,975,041	58,905,000	108.61%
2024-12-31	65,153,573	53,771,000	121.17%
2024-09-30	64,619,404	58,337,000	110.77%
2024-06-30	62,533,884	55,052,000	113.59%
2024-03-31	38,804,690	43,011,000	90.22%
2023-12-31	36,331,347	41,550,000	87.44%
2023-09-30	37,545,988	42,734,000	87.86%
2023-06-30	35,159,720	39,952,000	88.00%
Additional institutional holders are for subscribers only. Unlock the complete Form 13F ownership history Start 7-day free trial

Cullinan Therapeutics, Inc. (CGEM) — SEC Financial Statements & Analysis

Cullinan Therapeutics, Inc. (CGEM) is a biological products, (no diagnostic substances) company, incorporated in DE. Cullinan Therapeutics, Inc. trades on Nasdaq as: CGEM. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), Cullinan Therapeutics, Inc. reported a Debt-to-Equity ratio of 0.13x, a Price-to-Book (P/B) ratio of 3.64x (TTM), at a market cap of $1.17B. Figures below are sourced from SEC EDGAR, as-filed.

Debt To Equity: 0.13x
P/B TTM: 3.64x
Market Cap: $1.17B

Data as of 2026-06-30 · Source: SEC EDGAR

Frequently Asked Questions

What industry is Cullinan Therapeutics, Inc. in?

Cullinan Therapeutics, Inc. (CGEM) operates in the Biological Products, (No Diagnostic Substances) industry.

What is CGEM's market cap?

Cullinan Therapeutics, Inc. (CGEM) has a market capitalization of $1.17B as of 2026-06-30.

What exchange does CGEM trade on?

Cullinan Therapeutics, Inc. (CGEM) trades on the Nasdaq.

Where is Cullinan Therapeutics, Inc. incorporated?

Cullinan Therapeutics, Inc. is incorporated in DE.